Thrombospondin-1-Based Antiangiogenic Therapy.
Ocular angiogenesis is one of the underlying causes of blindness and vision impairment and may occur in a spectrum of disorders, including diabetic retinopathy, neovascular age-related macular degeneration, retinal artery or vein occlusion, and retinopathy of prematurity. As such, strategies to inhibit angiogenesis by suppressing vascular endothelial growth factor activity have proven to be effective in the clinic for the treatment of eye diseases. A complementary approach would be to increase the level of naturally occurring inhibitors of angiogenesis, such as thrombospondin (TSP)-1. This article summarizes the development of TSP-1-based inhibitors of angiogenesis.
Department of Pathology, Beth Israel Deaconess Medical Center , Harvard Medical School, Boston, Massachusetts.
Jennifer N
JN
Sims
Department of Pathology, Beth Israel Deaconess Medical Center , Harvard Medical School, Boston, Massachusetts.
Jack
J
Lawler
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001766:Blindness / Q000188:drug therapy / Q000209:etiology; D005123:Eye / Q000098:blood supply* / Q000187:drug effects* / Q000473:pathology; D005128:Eye Diseases / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D019700:Thrombospondin 1 / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D019700:Thrombospondin 1